Jazz Pharmaceuticals plc
- Open
- 238.94
- Day high
- 249.50
- Day low
- 238.08
- Prev close
- 242.18
- Volume
- 496K
- Mkt cap
- $15.5B
- P/E (TTM)
- 603.7
- EPS (TTM)
- $0.41
- P/B
- 3.4
- P/S
- 3.5
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$6.3M over the last 3 months (0 open-market buys, 8 sales)
- 🏛Institutions accumulating (13F)
Jazz Pharmaceuticals plc (JAZZ) is a Healthcare company listed on NASDAQ. The stock is up 119% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 8 sales (SEC Form 4).
Jazz Pharmaceuticals plc (JAZZ) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 12 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
JAZZ earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 5, 2026 | $4.67 | $6.34 | +35.8% | $1.1B | +9.2% |
| Feb 24, 2026 | $6.62 | $6.64 | +0.3% | $1.2B | +24.5% |
| Nov 5, 2025 | $5.95 | $8.13 | +36.6% | $1.1B | +1.3% |
| Feb 25, 2025 | $5.83 | $6.60 | +13.2% | $1.1B | +10.5% |
| Jul 31, 2024 | $4.68 | $5.30 | +13.2% | $1.0B | -1.3% |
| May 1, 2024 | $4.14 | $2.68 | -35.3% | $902M | -5.4% |
| Feb 28, 2024 | $5.26 | $5.02 | -4.6% | $1.0B | +5.7% |
| Mar 1, 2023 | $0.51 | $-0.07 | -113.7% | $972M | +8.6% |
| Nov 9, 2022 | $4.72 | $5.17 | +9.5% | $941M | +0.1% |
| Aug 3, 2022 | $4.20 | $4.30 | +2.4% | $933M | +3.4% |
| May 4, 2022 | $3.75 | $3.73 | -0.5% | $814M | -4.5% |
| Mar 1, 2022 | $3.71 | $4.21 | +13.5% | $897M | +3.8% |
JAZZ insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 6, 2026 | COZADD BRUCE Cdirector | Sell | 6,000 | $240.47 |
| Jul 2, 2026 | Johnson Philip Lofficer: EVP & Chief Financial Officer | Tax | 3,343 | $237.72 |
| Jul 2, 2026 | GALA RENEE Dofficer: President & CEO | Tax | 4,835 | $237.72 |
| Jul 2, 2026 | Iannone Robertofficer: EVP, Global Head of R&D & CMO | Tax | 3,764 | $237.72 |
| Jul 2, 2026 | Patil Neena Mofficer: EVP & Chief Legal Officer | Tax | 2,678 | $237.72 |
| Jul 2, 2026 | Pearce Samanthaofficer: EVP, Chief Commercial Officer | Tax | 2,527 | $237.72 |
| Jun 17, 2026 | Smith Mark Douglasdirector | Sell | 1,157 | $230.55 |
| Jun 12, 2026 | Patil Neena Mofficer: EVP & Chief Legal Officer | Sell | 1,200 | $231.83 |
| Jun 1, 2026 | Pearce Samanthaofficer: EVP, Chief Commercial Officer | Option | 6,907 | $109.45 |
| Jun 1, 2026 | Mulligan Seamusdirector | Option | 3,415 | $138.08 |
| Jun 1, 2026 | Patil Neena Mofficer: EVP & Chief Legal Officer | Sell | 1,192 | $236.97 |
| Jun 1, 2026 | Pearce Samanthaofficer: EVP, Chief Commercial Officer | Sell | 6,907 | $235.41 |
| May 27, 2026 | Winningham Rick Edirector | Option | 3,415 | $138.08 |
| May 27, 2026 | Winningham Rick Edirector | Sell | 2,741 | $241.57 |
| May 27, 2026 | McSharry Heather Anndirector | Sell | 2,000 | $241.00 |
Source: JAZZ SEC Form 4 filings, latest Jul 6, 2026. For informational purposes only — not investment advice.
See the full JAZZ insider & 13F page →Jazz Pharmaceuticals plc company profile
Overview
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is an Irish-domiciled biopharmaceutical company founded in 2003 that specializes in developing and commercializing treatments for rare neurological and oncological conditions. Originally incorporated as a small specialty pharmaceutical company, Jazz has grown through strategic acquisitions and internal development into a major player in the sleep medicine, epilepsy, and cancer treatment markets. The company went public in 2007 and has achieved 21 consecutive years of revenue growth, with 2024 revenues reaching $4.1 billion. Jazz operates globally with a focus on addressing unmet medical needs in neuroscience and oncology, maintaining a diversified portfolio of marketed products alongside a robust pipeline of investigational therapies.
Business
Jazz Pharmaceuticals operates in the biopharmaceutical industry, focusing on two primary therapeutic areas: neuroscience and oncology. The company develops, manufactures, and commercializes prescription medications for rare and serious medical conditions. The neuroscience portfolio represents approximately 60% of total revenues and centers around sleep disorders and neurological conditions. The flagship product is Xywav, an oral solution containing sodium oxybate used to treat excessive daytime sleepiness and cataplexy (sudden muscle weakness) in patients with narcolepsy, as well as idiopathic hypersomnia. Xywav is differentiated from its predecessor Xyrem by having significantly lower sodium content, making it safer for patients with cardiovascular concerns. The portfolio also includes Epidiolex, a purified cannabidiol (CBD) oral solution that treats seizures associated with rare forms of epilepsy including Lennox-Gastaut syndrome and Dravet syndrome. Epidiolex was the first FDA-approved prescription medication derived from cannabis. The oncology portfolio accounts for approximately 30% of revenues and includes treatments for various blood cancers and solid tumors. Key products include Zepzelca (lurbinectedin), a chemotherapy drug for treating metastatic small cell lung cancer; Rylaze, an enzyme therapy for acute lymphoblastic leukemia that breaks down the amino acid asparagine that cancer cells need to survive; and Ziihera (zanidatamab), a recently approved HER2-targeted therapy for biliary tract cancer. Additional oncology products include Vyxeos for acute myeloid leukemia and Defitelio for hepatic veno-occlusive disease. The remaining 10% of revenues comes from other specialized products and international operations. Jazz's approach focuses on rare diseases and conditions with limited treatment options, allowing the company to command premium pricing while serving critical medical needs.
Revenue model
Jazz Pharmaceuticals generates revenue primarily through direct product sales of prescription medications to hospitals, specialty pharmacies, and distributors. The company operates a specialized commercial model focused on rare diseases, which allows for premium pricing due to limited competition and high unmet medical need. The neuroscience business model relies heavily on specialty pharmacy distribution and direct patient support programs. Products like Xywav and Epidiolex require specialized handling, patient education, and insurance authorization support. Jazz maintains field teams of medical science liaisons and patient access coordinators who work directly with healthcare providers and patients to ensure proper treatment initiation and adherence. This high-touch approach creates strong relationships with prescribing physicians and helps maintain market share. The oncology business operates through hospital and clinic sales, where products are administered in controlled medical settings. Jazz's oncology products are typically used in specialized cancer centers and require coordination with oncologists, pharmacists, and infusion centers. The company provides medical affairs support and clinical data to help healthcare providers optimize treatment protocols. Several factors influence Jazz's profit margins. Positive margin drivers include the rare disease focus which supports premium pricing, patent protection on key products, economies of scale in manufacturing, and the company's direct sales model that eliminates intermediary markups. The specialized nature of Jazz's products creates high switching costs for patients and providers, supporting pricing power. Margin pressures come from generic competition (particularly the authorized generic for Xyrem), increasing research and development costs for pipeline programs, regulatory compliance expenses, and potential pricing pressure from payers and government entities. Manufacturing complexity for specialized formulations like Epidiolex's CBD extraction and Xywav's controlled substance requirements also impact costs. Additionally, the company faces currency exchange risks from international operations and potential patent cliff scenarios as key products lose exclusivity.
Competitive moat
Jazz Pharmaceuticals maintains a moderately strong competitive moat built primarily on regulatory barriers, specialized expertise, and switching costs, though this moat faces some vulnerabilities over time. The company's strongest defensive position comes from its regulatory and manufacturing expertise in complex, controlled substances and rare disease treatments. Products like Xywav require specialized manufacturing capabilities for controlled substances, while Epidiolex involves complex CBD extraction and purification processes that create barriers to generic entry. The company has built deep relationships with regulatory agencies and understands the intricate approval processes for rare disease treatments, giving it advantages in pipeline development. Switching costs and patient lock-in effects provide additional protection. Once patients are stabilized on treatments like Xywav or Epidiolex, physicians are reluctant to change therapies due to the complexity of titration and the severity of underlying conditions. Jazz's patient support programs, specialty pharmacy networks, and medical affairs teams create a comprehensive ecosystem that competitors would need to replicate. The rare disease focus itself provides some moat characteristics, as the small patient populations make it economically challenging for multiple competitors to justify development costs. This dynamic supports premium pricing and market share retention. However, Jazz's moat faces several potential threats. Patent expirations represent the most significant risk, with generic competition already impacting the oxybate franchise through authorized generics. Large pharmaceutical companies with greater resources could develop competing treatments, particularly in the larger opportunity areas like epilepsy and sleep disorders. Biosimilar competition may emerge for the company's protein-based oncology treatments. Additionally, changing treatment paradigms, such as new drug classes or combination therapies, could disrupt Jazz's established market positions. The moat is moderately durable but requires continuous investment in R&D and strategic acquisitions to maintain competitive positioning as patents expire and new competitors emerge.
Risks & safety
Jazz Pharmaceuticals demonstrates a strong financial safety profile with robust cash generation and manageable debt levels, though trading at elevated valuations. • Liquidity and Solvency: Excellent cash position of $1.86 billion with strong free cash flow generation of $391 million in Q1 2025. Current ratio of 3.38 indicates strong short-term liquidity. No immediate solvency concerns given consistent positive cash flows. • Debt Management: Debt-to-equity ratio of 1.30 is elevated but manageable for a pharmaceutical company. The company generates sufficient cash flow to service debt obligations and has demonstrated ability to reduce leverage over time. • Valuation Concerns: EV/EBITDA of 25.6x appears expensive, though this reflects the recent acquisition impact. Historical trading ranges suggest more reasonable valuations around 7-9x EBITDA during normal periods. • Other Considerations: Patent cliff risks for key products, particularly in the oxybate franchise, create medium-term revenue uncertainty. However, diversified product portfolio and strong pipeline provide some protection. Regulatory risks are inherent in pharmaceutical operations but company has strong track record of approvals.
Recent development
Over the past few years, Jazz Pharmaceuticals has executed several strategic pivots and expansions that have strengthened its market position and pipeline depth. The company has successfully transitioned its oxybate franchise from Xyrem to Xywav, with the low-sodium formulation now representing the majority of oxybate prescriptions. This transition has helped defend against generic competition while expanding into the idiopathic hypersomnia market, adding approximately 1,850 net patients in 2024. The oncology portfolio has been significantly enhanced through strategic acquisitions and pipeline development. The company acquired zanidatamab (now Ziihera), which received FDA approval for HER2-positive biliary tract cancer in late 2024. Jazz is preparing multiple regulatory submissions for Ziihera in additional indications including gastroesophageal adenocarcinoma and breast cancer, with peak sales potential estimated at over $2 billion across all indications. The company also advanced Zepzelca into first-line maintenance therapy for small cell lung cancer, with positive Phase 3 results leading to a planned supplemental NDA submission. Pipeline diversification efforts have included the recent acquisition of Chimerix, adding Dordaviprone for rare brain tumors, and continued development of the orexin receptor program JZP441 for narcolepsy. The company has also expanded Epidiolex's geographic footprint and is pursuing additional seizure indications, positioning the product to reach blockbuster status in 2025. Jazz has demonstrated disciplined capital allocation, maintaining strong cash generation while investing in high-potential assets. The company continues to evaluate corporate development opportunities across neuroscience, oncology, and rare diseases, with particular focus on assets that can leverage existing commercial infrastructure and expertise.
JAZZ company profile · for informational purposes only — not investment advice.
Track JAZZ with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free